Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 233

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 233
---
 industrial and commercial agreements in the field of innovative companies, including biotechnology companies, compliance and regulations and in business development. The Leadership Team meets at least once a month and deals with all subjects regarding the activities and the management of the Company.

As of December 31, 2024, the members of the Leadership Team were Jonathan Dickinson, Yannis Morel, Sonia Quaratino, Arvind Sood, Odile Belzunce, Odile Laurent, Nicola Beltraminelli, Claire de Saint Blanquat, Henry Wheeler and Frédéric Lombard. Eric Vivier, the Senior Vice President, Chief Scientific Officer, is a permanent guest to the meetings of the Leadership Team.

Corporate Governance Practices

As a general matter, the Company’s Supervisory Board practices comply with the recommendations of the Middlenext corporate governance code, with certain exceptions.

For an overview of Innate's corporate governance practices and the ways they may differ from Nasdaq’s corporate governance listing rules, see “ Item 16G. - Corporate Governance.”

Code of Ethics

The Company has adopted a Code of Ethics applicable to all of its employees and members of its Executive Board and Supervisory Board. The Code of Ethics is available on its website. The Company expects that any amendments to the Code of Ethics, or any waivers of its requirements, will be disclosed on its website.

Executive Compensation Arrangements

Except the arrangements described in “ Item 7. B - Related Party Transactions - Arrangements with the members of the Executive and Supervisory Boards,” there are no arrangements or understanding between Innate and any of the other members of the Executive and Supervisory Boards providing for benefits upon termination of their employment, other than as required by applicable law.

D. Employees

As of December 31, 2024, the Company had 181 employees. Pursuant to French law, employees of Innate Pharma are subject to the French national collective bargaining agreement of Pharmaceutical Industries ( Convention collective Nationale des Industries Pharmaceutiques). The Company believes that it maintains good relations with its employees. The following tables show the number of employees as of December 31, 2024, broken out by department:

  Full-time equivalent employees of Innate Pharma SA and Innate Pharma Inc.      As of December 31, 2024  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and development                                                                           135  
  General and administrative                                                                          36  
  Leadership Team                                                                                     10  
  Total